NLRP3 inhibitor for use in lowering the risk of cardiovascular diseases

WO2025068958A1PCT designated stage expired Publication Date: 2025-04-03NOVARTIS AG
View PDF 3 Cites 2 Cited by

Patent Information

Application Number
PCT/IB2024/059449
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-09-29
Filing Date
2024-09-27
Publication Date
2025-04-03

Smart Images

  • Figure IMGF000029_0001
    Figure IMGF000029_0001
  • Figure IMGF000029_0002
    Figure IMGF000029_0002
  • Figure IMGF000029_0003
    Figure IMGF000029_0003
Patent Text Reader

Abstract

The present disclosure relates to the field of pharmacy, particularly to a NLRP3 inhibitor, or a pharmaceutical combination comprising a NLRP3 inhibitor and at least one further therapeutic agent, for use in lowering the risk of or preventing cardiovascular events (CVE) or cardiovascular diseases (CVD) in subjects with a known heart disease, particularly in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations. The disclosure also relates to a method for lowering the risk of or preventing cardiovascular events (CVE) or cardiovascular diseases (CVD) in subjects with a known heart disease, particularly in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations, which involves administering a NLRP3 inhibitor or the combination; and to the use of a NLRP3 inhibitor or the combination for the manufacture of a medicament for lowering the risk of or preventing cardiovascular events (CVE) or cardiovascular diseases (CVD) in subjects with a known heart disease in subjects with a known heart disease, particularly in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Sulfonylureas and related compounds and use of same

    WO2016131098A1

  • Compounds and compositions for treating conditions associated with NLRP activity

    WO2019023147A1

  • Methods of treating or selecting a treatment for a subject resistant to TNF inhibitor using a NLRP3 antagonist

    WO2020010118A1

Cited By

  • NEK7 inhibitors

    US12709616B2

  • NLRP3 inhibitor for use in treating myeloid diseases

    WO2026120530A1